Further clinical trials are needed to evaluate the efficacy of combination therapies that inhibit BET and PARP, as this strategy has great potential to improve the prognoses of patients with SCLC with MYC paralog amplification or overexpression. This evidence concerns the gene MYC and small cell lung carcinoma.